Some of these alterations are located in receptor tyrosine kinases (RTK) genes (FGFR1, FGFR2, FGFR3, and FGFR4), which have important implications for the selection of anti-cancer therapies [19,20]. This evidence concerns the gene NTRK1 and cancer.